Pharmaceutical sales and the medical representative role

In short

Pharmaceutical selling is a business-to-professional activity: the medical representative (MR) does not sell to the patient but persuades a registered medical practitioner to prescribe, and then ensures the stock is available at the chemist so the prescription converts into a sale. It is governed by its own legal frame — Schedule H/H1 prescription-only status under the Drugs and Cosmetics Rules, 1945, the ban on advertising prescription drugs to the public, the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954, and the Uniform Code for Pharmaceutical Marketing Practices (UCPMP 2024) on gifts and hospitality. In B.Pharm it is examined in Pharmaceutical Marketing / Pharmacy Practice and Pharmaceutical Management papers (4Ps of marketing, channels, promotion mix, sales forecasting, drug store management). It is also the single largest recruiter of fresh B.Pharm and D.Pharm graduates in India — Sun Pharma, Cipla, Dr Reddy's, Lupin, Mankind, Alkem, Torrent, Zydus, Abbott India, USV, Intas and thousands of PCD franchise firms hire MRs, TBMs and ABMs every year, and the campus interview is almost entirely built on detailing skill, territory arithmetic and product knowledge.

Explained

What pharmaceutical selling is and how it differs from FMCG selling

• Separation of payer, decider and consumer: the doctor decides, the patient (or an insurer/government scheme) pays, the chemist dispenses. Promotion is therefore aimed at the prescriber, not the user.
• Ethical / prescription segment: Schedule H and H1 drugs can be sold only against a prescription of a registered medical practitioner and cannot be advertised to the public. Promotion = personal selling + literature + medical journals + CMEs.
• OTC / non-drug segment: vitamins, antacids, analgesic balms, ORS, cough syrups, nutraceuticals, cosmetics — can be mass-advertised, so FMCG-style push, trade schemes and consumer promotions apply.
• Generic-generic / trade generics: sold on trade margin to the chemist, who substitutes at the counter; the MR's customer here is the retailer and stockist, not the doctor.
• Institutional / hospital / government business: tenders, rate contracts, CGHS/ESIC/railways/state drug corporations; price-led, handled by key account or institutional teams, not by territory MRs.
• Consequences: small customer universe per territory (typically 150-250 doctors), high call frequency, no credit sale to the doctor, and sales measured indirectly (the MR never sees the actual prescription being written).

The medical representative: qualification, hierarchy, territory

• Designations: Medical Representative / Professional Service Representative / Territory Business Executive. Specialist variants: Hospital Representative, Key Account Executive, Scientific/Therapy Specialist, Critical Care Executive.
• Eligibility: B.Pharm, D.Pharm, B.Sc (Biology/Chemistry) typically; MNC and specialty divisions prefer B.Pharm or B.Sc + MBA. A two-wheeler, driving licence and willingness to relocate are near-universal requirements.
• Career ladder: MR → Area/Territory Business Manager (ABM/TBM, 4-8 MRs) → Regional Manager (RM/RSM) → Zonal Manager (ZSM) → Sales/Marketing Director; sideways moves into product management (brand manager), medical affairs (MSL), training, or sales force effectiveness/analytics.
• Territory structure: territory → area → region → zone. The MR works a fixed beat plan (a day-wise route of markets/doctors) — usually HQ days, ex-station day-trips and outstation tours; the beat repeats on a cycle, commonly 2 or 4 weeks so a Class A doctor is seen 2-4 times a month.
• Doctor classification (ABC / Class A-B-C): by prescription potential, not by friendliness. Class A gets maximum frequency; the rule of thumb is that roughly 20-30% of doctors generate 70-80% of business (Pareto).
• Reporting: daily call report (DCR) in an SFA app (e.g. mSales, SANeFORCE, Ebiz-type systems), tour programme submitted in advance, expense statement, sample and gift account, monthly review with the ABM.

The sales call: detailing, structure, objection handling

1. Pre-call planning: doctor's speciality, patient profile, last call's commitment, current brand being prescribed, which of my brands to detail (usually 2-3 products per call), the exact objective ("get him to start 10 patients a month on X 500 mg").
2. Opening: introduce self, company and purpose; respect the doctor's time (a typical call is 2-5 minutes).
3. Probing: open questions to find the unmet need — type of patients, dosing problems, tolerability, compliance, cost sensitivity.
4. Detailing: present the brand using the visual aid / detailing folder — indication, composition, mechanism, dose and duration, clinical evidence, safety, pack and price. Sequence of features → benefits → proof (a feature is what the product is, a benefit is what it does for the doctor's patient; always close the loop with published evidence or a reprint).
5. Objection handling: listen fully, acknowledge, clarify the real objection, answer with evidence, confirm acceptance. Common objections: "your price is higher", "I am happy with brand Y", "no clinical data in Indian patients", "not available at my chemist".
6. Close / commitment: ask for a specific prescription commitment and note it; a call without a commitment is a courtesy visit.
7. Post-call: record in DCR, ensure stock at the nearby chemists, follow up on the commitment in the next call.
8. Promotional inputs: visual aid, product monograph, leave-behind literature, journal reprints, clinical trial summaries, physician samples (must be marked "Physician's Sample — Not for Sale"), patient education material, reminder items of low value.
9. Scientific engagement: CMEs, round-table meetings, speaker programmes, conference booths, advisory boards — all now subject to the UCPMP conditions below.

The channel: CFA, stockist, chemist and the primary-secondary chain

• Flow: manufacturer → CFA (clearing and forwarding agent) who holds consignment stock in each state → stockist/distributor → retail chemist → patient. Some companies use super-stockists in deep rural markets.
• Primary sales: company → stockist (this is the company's invoiced/recognised sale). Secondary sales: stockist → chemist. Tertiary/offtake: chemist → patient. Bonuses are usually paid on secondary, which reflects real consumption.
• Why the distinction matters: pushing primary without secondary creates channel stuffing — inventory piles up, expiry and returns follow, and the next quarter's sales collapse. Healthy pipeline is normally judged against about one month's stock at the stockist.
• Trade terms: retailer margin on scheduled/branded formulations is commonly about 16% and stockist about 8-10% of MRP (DPCO-notified margins apply to scheduled drugs; trade generics carry far higher margins). Expiry/breakage goods are taken back as per company policy, usually through the stockist.
• MR's trade work: RCPA (retail chemist prescription audit) — reading the chemist's prescription records/bills to see which doctor prescribed what, in what strength, how much, and which competitor is winning; placing orders; checking stock and expiry (near-expiry/short-expiry); recovering outstanding only where the company permits; ensuring the brand is visible and not substituted.
• Legal checkpoints at the counter: retail sale against prescription for Schedule H; Schedule H1 requires a separate register with patient and prescriber details retained three years (antibiotics, anti-TB, some sedatives); Schedule X needs special licence and records; cold chain for vaccines and insulin (2-8 °C); a registered pharmacist must be present (Pharmacy Act, 1948).

Law, codes and ethics that bind promotion in India

• Drugs and Cosmetics Act, 1940 and Rules, 1945: licensing, labelling, Schedules H, H1, X; physician samples' limits and labelling; the New Drugs and Clinical Trials Rules, 2019 govern what claims a new drug may carry.
• Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954: prohibits advertisement of drugs claiming to cure the listed diseases/conditions and of "magic remedies"; penalties on conviction.
• No advertisement of prescription drugs to the public — the basis of the whole MR model; information to doctors is "promotion", not advertising.
• UCPMP 2024 (Department of Pharmaceuticals, in effect from 12 March 2024; it replaced UCPMP 2015 and is still enforced through industry associations' Ethics Committees for Pharmaceutical Marketing Practices rather than by statute): no gifts or pecuniary benefits to prescribers or their families; no travel/hospitality except to speakers at genuine CMEs; brand reminders capped in value (the 2024 code sets a low per-item and per-year limit — the exact figures are prescribed in the code and may be revised, so quote the code rather than a number from memory); continuing medical education must be through well-defined, disclosed arrangements; claims must be accurate, up to date and capable of substantiation; samples only to qualified prescribers, limited quantity, 12-month per-product cap per doctor in the 2024 code.
• Income-tax disallowance: expenditure on freebies to medical practitioners that violates the medical council/UCPMP regulations is not allowed as business expenditure — this rule continues under the Income-tax Act, 2025 (in force from 1 April 2026, which renumbered the 1961 Act's sections); the related tax deduction on benefits provided to a resident in the course of business also applies to such perquisites.
• National Medical Commission professional conduct regulations bind the doctor's side — doctors may not accept gifts, travel or hospitality from industry.
• Pricing: DPCO 2013 under the Essential Commodities Act, administered by NPPA — ceiling prices for scheduled formulations in the National List of Essential Medicines, annual WPI-linked revision, and a cap of up to 10% a year on increases for non-scheduled drugs. Selling above the ceiling price invites recovery with interest. GST on most medicines is 5% (slabs since 22 September 2025 are 5%/18%/40%; many lifesaving drugs are nil-rated — confirm the current rate for a given molecule).
• Other: Legal Metrology packaged commodity rules for pack declarations; Pharmacy Practice Regulations, 2015 for pharmacists; bar code/track-and-trace requirement on the top 300 brands for authentication.

Targets, measurement and field force effectiveness

• Sales target setting: top-down (company growth number cascaded) or bottom-up (territory potential × share aspiration), usually reconciled; divided into brand-wise and month-wise targets with seasonality (antibiotics and anti-allergics peak in monsoon and winter).
• Core MR metrics: call average (doctor calls per working day, usually 10-14 expected), coverage (% of listed doctors met in the cycle), frequency (calls per doctor per month), prescription share from RCPA, secondary sales achievement %, new-doctor additions, sample-to-sales ratio, expiry/return %.
• Market data: IQVIA/SMSRC-type secondary audit panels give market size and brand share by therapy and region; the MR's territory truth comes from RCPA.
• Compensation: CTC = gross salary + daily allowance (DA) + travel allowance (TA/fuel per km) + incentive. Incentives are typically slab-based on achievement %, often with a gate (no incentive below ~85-90% achievement) and brand-wise weightage on focus products.
• Growth arithmetic: value growth = price effect + volume effect + new-product effect; a brand can show value growth on a DPCO price rise while volume falls — examiners and interviewers both like this point.
• Models of going to market: own field force (large brands), PCD/franchise (monopoly rights to a distributor in a district), co-marketing/in-licensing (two brands of one molecule), institutional tender, and digital detailing / e-detailing (video calls, WhatsApp-based literature, doctor apps) which grew sharply after 2020.

Key points

• Ethical promotion - prescription (Schedule H/H1) drugs may be promoted only to prescribers; advertising them to the public is prohibited.
• MR's real job - generate prescriptions from doctors and ensure availability at chemists; sale happens at the counter, not in the clinic.
• Detailing - a structured 2-5 minute scientific presentation of a brand using a visual aid, moving features → benefits → proof.
• RCPA - retail chemist prescription audit; the only direct way an MR measures his and competitors' prescription share in a territory.
• Beat plan - the fixed day-wise route of doctors and chemists, repeated on a 2- or 4-week cycle.
• ABC classification - doctors graded A/B/C by prescription potential; call frequency follows the grade (Pareto: ~20-30% of doctors give ~70-80% of business).
• Call average - doctor calls per working day; the standard productivity measure, typically 10-14.
• Primary vs secondary sales - company→stockist vs stockist→chemist; incentives on secondary prevent channel stuffing.
• CFA - clearing and forwarding agent holding consignment stock state-wise; not a buyer, so no margin, only a service fee.
• Trade margins - about 16% retailer and 8-10% stockist on scheduled/branded formulations; much higher on trade generics.
• Physician sample - labelled "Physician's Sample — Not for Sale", limited quantity, never to be sold; UCPMP 2024 caps per doctor per product per year.
• UCPMP 2024 - the Department of Pharmaceuticals' marketing practices code in force from 12 March 2024; bans gifts, travel and hospitality to prescribers; self-regulatory, enforced through association ethics committees.
• DMD Act, 1954 - bans objectionable advertisements and magic-remedy claims for drugs.
• DPCO 2013 / NPPA - ceiling prices for NLEM scheduled formulations; non-scheduled prices may rise up to 10% a year.
• Schedule H1 register - separate record of sale with prescriber and patient details, kept three years; applies to specified antibiotics, anti-TB and psychotropics.
• Tax rule on freebies - benefits to doctors that breach the professional/UCPMP code are disallowed as business expenditure (carried into the Income-tax Act, 2025).
• Objection handling - listen, acknowledge, clarify, answer with evidence, confirm; price objections are answered with cost of therapy per day, not with discounts.
• Career path - MR → ABM/TBM → RM → ZSM, or sideways to product management, medical affairs, training and analytics.

Formulas and examples

Example 1 — Call average, coverage and frequency. An MR has 220 listed doctors (40 A, 70 B, 110 C). In a 4-week cycle he works 24 days and makes 288 calls, meeting 176 distinct doctors.

• Call average = 288 ÷ 24 = 12 calls/day.
• Coverage = 176 ÷ 220 × 100 = 80%.
• If 160 of the calls were on Class A doctors, A-frequency = 160 ÷ 40 = 4 calls per A doctor per cycle; the remaining 128 calls on the 180 listed B+C doctors ≈ 0.71 call each — so B doctors are being under-called, and the beat plan needs rebalancing.

Example 2 — RCPA and prescription share. At one chemist, a month's audit of a 500 mg antibiotic shows: my brand 60 strips, competitor P 90 strips, competitor Q 50 strips, others 50 strips. Total = 60 + 90 + 50 + 50 = 250 strips.

• My share = 60 ÷ 250 × 100 = 24%; P = 36%; Q = 20%; others = 20%.
• To reach 32% share at the same market size: required units = 0.32 × 250 = 80 strips, i.e. 20 extra strips a month — about 2 extra patients a month at a 10-strip course, a credible call objective.

Example 3 — Margins, PTR and PTS. A tablet pack has MRP ₹120. Retailer margin 16% of MRP, stockist margin 8% of MRP.

• Retailer buys at PTR = 120 × (1 − 0.16) = ₹100.80.
• Stockist's selling price = PTR = ₹100.80; stockist buys at PTS = 120 × (1 − 0.16 − 0.08) = ₹91.20.
• Stockist's earning per pack = 100.80 − 91.20 = ₹9.60; retailer's = 120 − 100.80 = ₹19.20.
• Cost of therapy: pack of 10 tablets, one tablet twice a day → 120 ÷ 10 × 2 = ₹24 per day; a 5-day course = ₹120. Against a competitor at ₹30/day, the saving over a 5-day course is ₹30 — the number to quote, not "we are cheaper".

Example 4 — Target, achievement and incentive. Monthly secondary target ₹6,00,000; actual ₹5,55,000. Incentive scheme: nil below 90%, 2% of achieved value from 90% to 99.99%, 3% from 100% to 109.99%, 4% at 110% and above.

• Achievement = 5,55,000 ÷ 6,00,000 × 100 = 92.5% → 2% slab → incentive = 0.02 × 5,55,000 = ₹11,100.
• To reach the 3% slab he needs ₹6,00,000, i.e. ₹45,000 more (an 8.1% lift on the achieved figure); that would pay 0.03 × 6,00,000 = ₹18,000 — ₹6,900 more for ₹45,000 of extra sales.

Example 5 — Primary, secondary and stock cover. Opening stock at stockists ₹4,00,000; primary billed in the month ₹7,00,000; secondary sales ₹5,00,000.

• Closing stock = 4,00,000 + 7,00,000 − 5,00,000 = ₹6,00,000.
• Stock cover = 6,00,000 ÷ 5,00,000 = 1.2 months against a norm of about 1 month — mild overstocking; if primary is pushed at this rate again, cover rises to 1.6 months and near-expiry returns begin. Correct action is to hold primary and work on secondary.

Where it is used

• Domestic formulations field force: Sun Pharma, Cipla, Dr Reddy's, Mankind, Alkem, Torrent, Zydus, Lupin, Intas, Abbott India, USV, Micro Labs, Ajanta — divisional structures by therapy (cardio-diabetes, anti-infectives, gastro, derma, gynaec, paediatrics, neuro-psychiatry).
• Specialty and hospital selling: oncology, critical care, nephrology, anaesthesia — Hospital Representatives dealing with hospital pharmacies, purchase committees and institutional tenders (CGHS, ESIC, state medical services corporations).
• PCD / franchise and trade-generic markets: monopoly-based district franchises (concentrated in Baddi, Panchkula, Ahmedabad, Indore belts) and generic-generic chains such as Jan Aushadhi outlets, where the chemist's margin drives the sale.
• Devices, diagnostics and nutraceuticals: surgical, ortho implant and diagnostic-kit sales use the same detailing and territory discipline with longer sales cycles and tender work.
• Head-office roles built on field knowledge: product/brand management, sales training, sales force effectiveness and CRM analytics, medical affairs (MSL), regulatory and pharmacovigilance interfaces for promotional claims.
• Community and retail pharmacy chains: Apollo Pharmacy, MedPlus, Wellness Forever, and e-pharmacies — category buying, private label and compliance with Schedule H1 and cold chain.

Interview questions

• Q: Why does a pharmaceutical company need an MR when it could advertise the product? A: Prescription drugs (Schedule H/H1) cannot legally be advertised to the public, and the prescribing decision is technical, so a trained representative must carry scientific information directly to the doctor.
• Q: What is detailing? A: The structured, evidence-based presentation of a brand to a doctor using a visual aid — indication, composition, dose, clinical evidence, safety, pack and price — ending with a request for a specific prescription commitment.
• Q: What is RCPA and why do you do it? A: Retail chemist prescription audit — reading chemist records to find which doctor prescribed which brand and how much; it reveals my real prescription share, competitor activity and whether a doctor's verbal commitment is translating into prescriptions.
• Q: Difference between primary and secondary sales? A: Primary is the company's invoiced sale to the stockist; secondary is the stockist's sale to retail chemists. Secondary reflects actual consumption, so pushing primary without secondary only builds stock that comes back as expiry.
• Q: How will you handle "your brand is costlier than X"? A: Shift the discussion from pack price to cost of therapy per day and per course, quantify the difference in rupees, and justify any premium with efficacy, tolerability, dosing convenience or compliance evidence — never by offering the doctor something.
• Q: What does UCPMP 2024 stop you from doing? A: Giving gifts, cash, travel or hospitality to a prescriber or family, making unsubstantiated claims, or funding doctors' conference travel except as a genuine CME speaker; brand reminders are value-capped and samples are limited per doctor per product per year.
• Q: How do you classify doctors in your territory? A: By prescription potential into Class A/B/C using patient load, speciality, relevance to my therapy and RCPA evidence — then allocate call frequency to the grade, not to personal comfort.
• Q: A doctor assures you 10 patients a month but RCPA shows nothing. What do you do? A: Check whether the stock is available and not being substituted at the chemists he uses, verify the right chemist is being audited, then re-detail to find the real objection instead of accepting the assurance.
• Q: Which schedule covers prescription drugs, and what is special about Schedule H1? A: Schedule H drugs are prescription-only; Schedule H1 (specified antibiotics, anti-TB and psychotropics) additionally require a separate register recording the prescriber and patient details, retained for three years, to curb antimicrobial misuse.
• Q: Who fixes medicine prices in India? A: NPPA under DPCO 2013 fixes ceiling prices for scheduled formulations in the NLEM; non-scheduled formulations are free-priced but cannot be raised by more than 10% in a year.
• Q: What is your call average and how would you raise it without harming quality? A: Typically 10-14 calls a day; it is raised by tighter beat planning that clusters doctors geographically, fixed appointment timings, and cutting travel — not by shortening the detailing or skipping the close.
• Q: Why should a B.Pharm graduate join field sales rather than production or QA? A: It converts pharmacology and pharmacotherapeutics knowledge into a commercial skill, gives the fastest exposure to therapy areas and customers, and is the standard entry route into brand management and sales leadership.

Common mistakes

• Saying the MR "sells medicine to the doctor" — nothing is sold to the doctor; the sale is at the chemist and the doctor only prescribes.
• Treating primary sales as achievement and ignoring stock cover and expiry — the classic channel-stuffing error.
• Quoting pack MRP instead of cost of therapy per day when answering a price objection, or conceding a discount the MR has no authority to give.
• Calculating trade margin on purchase price when Indian pharma convention expresses retailer and stockist margins on MRP.
• Writing in exams that prescription drugs may be advertised if claims are true — the prohibition is absolute for Schedule H/H1, and the DMD Act, 1954 bans objectionable and magic-remedy claims outright.
• Quoting the withdrawn UCPMP 2015 or the old MCI code instead of UCPMP 2024, or assuming the code is a statute — it is enforced through association ethics committees, with tax disallowance as the financial deterrent.
• Making a call with no pre-set objective and no closing commitment, then recording it in the DCR as a productive call.

Related topics

• Hospital and community pharmacy · Pharmaceutical marketing and the 4Ps · Pharmaceutical jurisprudence: Drugs and Cosmetics Act and Rules · DPCO, NPPA and drug pricing · Pharmacovigilance and adverse drug reaction reporting · Pharmacoeconomics and cost of therapy.